NPC's John O'Brien to Speak at Asembia's AXS25 Summit

NPC President and CEO John M. O'Brien, PharmD, MPH will be participating in two panel discussions as part of Asembia's Specialty Pharmacy Summit, April 27 - May 1, 2025 in Las Vegas. 

How the ‘Patient-as-Payer’ Era Is Transforming Patient Access & Affordability

April 29, 2025 | 3:00 PM-3:40 PM PT

Pharmaceutical companies have relied on a tried-and-true playbook for the past few decades to include access and affordability considerations in their brands’ go-to-market strategies. Now, in the era of the patient-as-payer, this playbook is no longer effective for pharma and other healthcare stakeholders. As the out-of-pocket (OOP) cost burden for patients continues to grow each year, stakeholders must integrate access and affordability into the DNA of how they operate and make decisions. This expert panel will provide a range of stakeholder perspectives on why addressing access and affordability is fundamental to healthcare organizations’ survival, and how to thrive in an era in which medication affordability may matter as much as positioning, promotion, and the patient journey.

Panel: 

• Dorothy Gemmell, Chief Commercial Officer & President, Manufacturer Solutions, GoodRx
• Helmuth Fendel, Vice President, US Market Access Account Management, Trade & 340B Center of Excellence, AbbVie
• Jennifer Norton, Senior Vice President of U.S. Patient and Market Access (PAMA), Takeda
• John Daly, Head, US PSS NA, Sanofi
• John M. O'Brien, President and Chief Executive Officer, National Pharmaceutical Council 

Value / Outcome-Based Specialty Contracting - Where We Are, Where We're Headed and What is the Endpoint/Outcome?

Tuesday, April 29, 2025 | 4:00 PM-4:40 PM PT

Join this session to hear from an expert panel on the future ahead for value/outcome-based contracting for high-cost specialty care.  Panelists will explore the transformative potential of aligning treatment outcomes with cost-efficiency, ensuring patients receive high-quality care while minimizing suboptimal clinical and financial results. Industry leaders will discuss the opportunities in personalized medicine, innovative therapies, elite technologies and evidenced AI driven approaches to improve patient outcomes. However, the panel will also address significant challenges, such as healthcare disparities, regulatory hurdles, and the integration of new technologies with legacy platforms into existing care models.

Panel:

• Burt Zweigenhaft, Founder, Association of Value Based Cancer Care
• John M. O'Brien, President and Chief Executive Officer, National Pharmaceutical Council (NPC)
• Kent Rogers, Chief Executive Officer / Venture Partner, EveryONE Medicines / ARCH Venture Partners
• Jayson Slotnik, Partner, Health Policy Strategies
• Nancy Bell, Vice President, Head of Market Access, Celuity
• Roxie Schwans, SVP, Industry Relations, Prime Therapeutics